Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Imunon, Inc. stock logo
IMNN
Imunon
$6.60
-1.5%
$11.55
$4.83
$41.22
$16.36M2.16488,885 shs63,040 shs
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
$2.34
+4.0%
$2.70
$1.72
$15.70
$4.50M0.2968,942 shs96,814 shs
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
$1.17
-6.4%
$1.91
$0.67
$2.60
$17.08M1.64411,842 shs479,081 shs
Trinity Biotech PLC stock logo
TRIB
Trinity Biotech
$1.91
+89.1%
$0.75
$0.48
$3.44
$18.24M0.77696,129 shs208.15 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Imunon, Inc. stock logo
IMNN
Imunon
-2.05%-18.49%-14.10%-20.47%-58.64%
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
+1.81%-0.88%-29.02%-23.47%-20.10%
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
+11.61%-6.72%-37.50%-0.79%+78.57%
Trinity Biotech PLC stock logo
TRIB
Trinity Biotech
-10.62%+21.66%+36.25%+20.78%-58.94%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Imunon, Inc. stock logo
IMNN
Imunon
1.868 of 5 stars
3.42.00.00.02.40.00.6
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
1.3388 of 5 stars
0.05.00.00.03.40.00.6
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
2.3864 of 5 stars
3.53.00.00.02.51.70.0
Trinity Biotech PLC stock logo
TRIB
Trinity Biotech
1.2833 of 5 stars
0.04.00.00.02.51.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Imunon, Inc. stock logo
IMNN
Imunon
2.75
Moderate Buy$232.503,422.73% Upside
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
0.00
N/AN/AN/A
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
3.00
Buy$14.001,096.58% Upside
Trinity Biotech PLC stock logo
TRIB
Trinity Biotech
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest INM, IMNN, NRSN, and TRIB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/10/2025
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$14.00
5/19/2025
Imunon, Inc. stock logo
IMNN
Imunon
D Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/19/2025
Imunon, Inc. stock logo
IMNN
Imunon
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Imunon, Inc. stock logo
IMNN
Imunon
$500K32.21N/AN/A$1.09 per share6.06
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
$4.60M1.02N/AN/A$20.64 per share0.11
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
N/AN/AN/AN/A($0.04) per shareN/A
Trinity Biotech PLC stock logo
TRIB
Trinity Biotech
$61.56M0.56N/AN/A($1.95) per share-0.98
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Imunon, Inc. stock logo
IMNN
Imunon
-$18.62M-$12.95N/AN/AN/AN/A-405.07%-158.41%N/A
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
-$7.68M-$12.09N/AN/A-168.87%-107.93%-82.97%9/26/2025 (Estimated)
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
-$10.21M-$0.54N/AN/AN/AN/A-445.40%9/29/2025 (Estimated)
Trinity Biotech PLC stock logo
TRIB
Trinity Biotech
-$31.79M-$2.93N/AN/AN/A-68.48%N/A-32.33%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Imunon, Inc. stock logo
IMNN
Imunon
N/AN/AN/AN/AN/A
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
N/AN/AN/AN/AN/A
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
N/AN/AN/AN/AN/A
Trinity Biotech PLC stock logo
TRIB
Trinity Biotech
N/AN/AN/AN/AN/A

Latest INM, IMNN, NRSN, and TRIB Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/28/2025
Imunon, Inc. stock logo
IMNN
Imunon
quarterly$0.158.57%8/7/20258/7/20258/21/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Imunon, Inc. stock logo
IMNN
Imunon
N/A
1.30
1.30
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
0.06
3.49
3.04
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
N/A
0.71
2.21
Trinity Biotech PLC stock logo
TRIB
Trinity Biotech
N/A
1.17
0.50

Institutional Ownership

CompanyInstitutional Ownership
Imunon, Inc. stock logo
IMNN
Imunon
4.47%
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
20.12%
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
1.04%
Trinity Biotech PLC stock logo
TRIB
Trinity Biotech
78.97%

Insider Ownership

CompanyInsider Ownership
Imunon, Inc. stock logo
IMNN
Imunon
5.96%
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
1.43%
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
27.40%
Trinity Biotech PLC stock logo
TRIB
Trinity Biotech
8.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Imunon, Inc. stock logo
IMNN
Imunon
302.44 million2.30 millionNot Optionable
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
102.00 million1.97 millionNot Optionable
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
1013.67 million9.92 millionNot Optionable
Trinity Biotech PLC stock logo
TRIB
Trinity Biotech
48018.05 million16.57 millionOptionable

Recent News About These Companies

Trinity Biotech reports its 15-day CGM works without fingersticks
Trinity Biotech reports positive outcomes with next-gen CGM sensor
Trinity unveils AI-powered CGM+ biosensor
Trinity Biotech unveils next-gen AI-powered CGM biosensor

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Imunon stock logo

Imunon NASDAQ:IMNN

$6.60 -0.10 (-1.49%)
Closing price 04:00 PM Eastern
Extended Trading
$6.62 +0.02 (+0.23%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.

InMed Pharmaceuticals stock logo

InMed Pharmaceuticals NASDAQ:INM

$2.34 +0.09 (+4.00%)
Closing price 04:00 PM Eastern
Extended Trading
$2.29 -0.05 (-2.14%)
As of 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

NeuroSense Therapeutics stock logo

NeuroSense Therapeutics NASDAQ:NRSN

$1.17 -0.08 (-6.40%)
Closing price 04:00 PM Eastern
Extended Trading
$1.17 0.00 (-0.09%)
As of 06:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.

Trinity Biotech stock logo

Trinity Biotech NASDAQ:TRIB

$1.91 +0.90 (+89.05%)
Closing price 04:00 PM Eastern
Extended Trading
$1.60 -0.31 (-15.97%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. The company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.